Industry observers are closely watching for fresh fallout among telehealth providers. For one, the declared end of the semaglutide drug shortage—as per the Food and Drug Administration—sent the stock of Hims & Hers Health, Inc. sliding about 40% within just a few days as investors realized the profits coming from compounding semaglutide for the telehealth company’s patients will quickly dwindle as providers must shift back to the manufacturer’s original brand drug products for weight management …
Read More